Download PDF
Nuklearmedizin 2022; 61(01): 62-64
DOI: 10.1055/a-1670-9315
Case Report

18F Choline PET/CT in a patient with HRPT2 mutation: Detecting parathyroid carcinoma recurrence and concomitant breast carcinoma

18F Choline PET/CT bei einer Patientin mit HRPT2 Mutation: simultane Erfassung eines Rezidives eines Nebenschilddrüsenkarzinoms und eines Mammakarzinoms
Konrad Christof Radzikowski
1   Department of Nuclear Medicine & Endocrinology, Paracelsus Medical University Salzburg, Salzburg, Austria (Ringgold ID: RIN31507)
,
Gundula Rendl
1   Department of Nuclear Medicine & Endocrinology, Paracelsus Medical University Salzburg, Salzburg, Austria (Ringgold ID: RIN31507)
,
Mohsen Beheshti
1   Department of Nuclear Medicine & Endocrinology, Paracelsus Medical University Salzburg, Salzburg, Austria (Ringgold ID: RIN31507)
,
Christian Pirich
1   Department of Nuclear Medicine & Endocrinology, Paracelsus Medical University Salzburg, Salzburg, Austria (Ringgold ID: RIN31507)
› Author Affiliations
› Further Information
    Permissions and Reprints

Introduction

Parathyroid carcinoma (PC) is a rare neoplasm with an estimated incidence less than 1% of all cases of primary hyperparathyroidism (PHPT) [1]. Patients mostly present with primary hyperparathyroidism and excessively high PTH and calcium levels, but final diagnosis can only be established by histopathological examination. A wide spectrum of biologic behavior has been reported, ranging from a fulminant course leading to death within weeks to slow progression of the disease over years. In contrast to the well acknowledged value of 99m-Tc-MIBI scintigraphy in parathyroid adenoma, there are few reports on its diagnostic value in PC. Recently, 18F Choline PET/CT has shown to be a promising imaging modality for parathyroid adenoma beyond its use in prostate carcinoma and now plays a growing role in the workup of benign and possibly also in malignant tumors of the parathyroid gland [2].



Publication History

Received: 06 April 2021

Accepted after revision: 14 October 2021

Article published online:
29 November 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Weber T. et al. S2k-Leitlinie: Operative Therapie des primären und renalen Hyperparathyreoidismus. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)- Ständige Kommission Leitlinien 2020. Available via: https://www.awmf.org/leitlinien/detail/ll/088–009.html (accessed August 02, 2021).
    Google Scholar
  • 2 Beheshti M, Hehenwarter L, Paymani Z. et al. (18)F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with (99m)Tc-MIBI or (99m)Tc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients. Eur J Nucl Med Mol Imaging 2018; 45: 1762-1771 DOI: 10.1007/s00259-018-3980-9. (PMID: 29516131)
    CrossrefPubMedGoogle Scholar
  • 3 Schweighofer-Zwink G, Hehenwarter L, Rendl G. et al. Imaging of parathyroid adenomas with F‑18 choline PET-CT. Wien Med Wochenschr 2019; 169: 15-24 DOI: 10.1007/s10354-018-0660-0. (PMID: 30264384)
    CrossrefPubMedGoogle Scholar
  • 4 Salcuni AS, Cetani F, Guarnieri V. et al. Parathyroid carcinoma. Best Pract Res Clin Endocrinol Metab 2018; 32: 877-889 DOI: 10.1016/j.beem.2018.11.002. (PMID: 30551989)
    CrossrefPubMedGoogle Scholar
  • 5 Nilsson IL, Zedenius J, Yin L. et al. The association between primary hyperparathyroidism and malignancy: nationwide cohort analysis on cancer incidence after parathyroidectomy. Endocr Relat Cancer 2007; 14: 135-140 DOI: 10.1677/erc.1.01261. (PMID: 17395982)
    CrossrefPubMedGoogle Scholar